Indigo. Glucose managed on-the-go.
Go without finger prick
Indigo develops the next-gen needle-free glucose sensors for diabetics. Indigo’s first product addresses the need for accurate, low-cost glucose monitoring systems with an optimal user experience.
Who we are
Indigo is a spin-off from Ghent University and imec.
Indigo’s needle-free glucose sensor exploits a groundbreaking photonics technology that was developed at Ghent University and imec by Indigo’s Founders.
The Executive Team
Danaë Delbeke, PhD, General Manager, co- inventor and co-founder
Koenraad Van Schuylenbergh, PhD, CTO, and co-founder
Wim Pollet, MD, CMO, and co-founder
The Investors
The funding is provided by an international investment syndicate led by Thuja Capital Healthcare Fund II and PMV, and includes Sensinnovat, Parana Management Corp, Qbic Arkiv Fund, Fidimec, SOFI, Manuardeo and Capricorn ICT Arkiv as co-investors.
Indigo
The colour indigo owes its position in the colour spectrum to Isaac Newton, who established Indigo as being the 7th colour. Indigo is neither a primary nor a secondary colour. The human eye is hardly capable to detect the nuances of Indigo, so it takes a specific sensitivity to mark the colour variety. However Newton added for reasons of perfection indigo to the set of 6 primary and secondary colours (red, orange, yellow, green, blue, violet) to have the spectrum in accordance to music (7 notes), the seven heavenly bodies (planets and sun and moon) who were then known, the seven days in a week.
So indigo is the light that was missing to make it perfect, and that is Indigo’s mission.
News
December 19 2016, Ghent Belgium – Indigo Announces successful series A financing round
Spin-off from UGent and imec is launched to develop the next generation needle-free glucose sensors, paving way to a paradigm shift in diabetes management.
A paradigm shift
“Worldwide, the number of diabetic patients has increased from 108 million in 1980 to 422 million in 2014 according to the World Health Organization. With so many individuals reliant on frequent glucose measurements to help manage this disease, we eagerly support Indigo as it holds the potential to enable a paradigm shift in diabetes management with a game-changing technology.” – Harrold van Barlingen, managing director of Thuja Capital.
